0000899243-22-016538.txt : 20220504
0000899243-22-016538.hdr.sgml : 20220504
20220504090258
ACCESSION NUMBER: 0000899243-22-016538
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220504
FILED AS OF DATE: 20220504
DATE AS OF CHANGE: 20220504
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Gollob Jared
CENTRAL INDEX KEY: 0001821198
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39460
FILM NUMBER: 22889983
MAIL ADDRESS:
STREET 1: C/O KYMERA THERAPEUTICS, INC.
STREET 2: 200 ARSENAL YARDS, SUITE 230
CITY: WATERTOWN
STATE: MA
ZIP: 02472
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Kymera Therapeutics, Inc.
CENTRAL INDEX KEY: 0001815442
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 812992166
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 200 ARSENAL YARDS BLVD., SUITE 230
CITY: WATERTOWN
STATE: MA
ZIP: 02472
BUSINESS PHONE: 857-285-5314
MAIL ADDRESS:
STREET 1: 200 ARSENAL YARDS BLVD., SUITE 230
CITY: WATERTOWN
STATE: MA
ZIP: 02472
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-05-04
0
0001815442
Kymera Therapeutics, Inc.
KYMR
0001821198
Gollob Jared
C/O KYMERA THERAPEUTICS, INC.
200 ARSENAL YARDS BLVD., SUITE 230
WATERTOWN
MA
02472
0
1
0
0
Chief Medical Officer
Common Stock
2022-05-04
4
M
0
10208
1.31
A
47465
D
Common Stock
2022-05-04
4
M
0
9792
2.08
A
57257
D
Stock Option (Right to Buy)
1.31
2022-05-04
4
M
0
10208
0.00
D
2028-10-31
Common Stock
10208
29799
D
Stock Option (Right to Buy)
2.08
2022-05-04
4
M
0
9792
0.00
D
2029-05-22
Common Stock
9792
109020
D
Twenty-five percent (25%) of the shares underlying this stock option vested on September 12, 2019 and the remaining shall vest in equal monthly installments over the remaining thirty-six (36) months, subject to the reporting person's continued employment through each vesting date.
The shares underlying this stock option shall vest in forty-eight (48) equal monthly installments following the vesting commencement date of February 7, 2019, subject to the reporting person's continued employment through each vesting date.
/s/ Bruce N. Jacobs, as Attorney-in-Fact
2022-05-04